ライフサイエンスコーパス: thrombocytopenic

1 weeks of drug (90% vs. 26%), to be severely thrombocytopenic (84% vs. 60%), and to have normal renal

2 s, and angiogenesis was nearly identical for thrombocytopenic and control mice.

3 pletion of neutrophils prevented bleeding in thrombocytopenic and GPVI(-/-) mice during IC-mediated d

4 trophil cytotoxic activities were reduced in thrombocytopenic and GPVI(-/-) mice during IC-mediated i

5 ysis of blood smears from healthy donors and thrombocytopenic and sickle cell disease patients.

6 syndrome or acute myeloid leukaemia who are thrombocytopenic and unable to receive disease-modifying

7 loma; however, many of these patients become thrombocytopenic, and it is not clear how the proteasome

8 re not appreciably altered in mice that were thrombocytopenic, anemic, or leukopenic.

9 indicate that for severe thrombocytopenia or thrombocytopenic bleeding in the third trimester, intrav

10 normal platelet numbers at E12.5 but became thrombocytopenic by E15.5, suggesting that c-myb is requ

11 Adult mice were rendered thrombocytopenic by i.p. administration of an antiplatel

12 s of wound healing, adult mice were rendered thrombocytopenic by intraperitoneal administration of a

13 platelet counts in adult mice that were made thrombocytopenic by tamoxifen-induced suppression of pro

14 cy of these new agents in a variety of other thrombocytopenic conditions.

15 e HIT), defined as a transient prothrombotic thrombocytopenic disorder without proximate heparin expo

16 gnosis remains one of exclusion, after other thrombocytopenic disorders are ruled out based on histor

17 une thrombocytopenia, or patients with other thrombocytopenic disorders, the authors concluded that,

18 of TPO-RAs, both in ITP as well as in other thrombocytopenic disorders.

19 nt of ITP, both agents could help treat many thrombocytopenic disorders.

20 ld soon be clinically available for treating thrombocytopenic disorders.

21 iology of von Willebrand disease and related thrombocytopenic disorders.

22 may result in a liver xenograft with reduced thrombocytopenic effects, which could be used as a bridg

23 site primary endpoint of clinically relevant thrombocytopenic events (CRTE) during weeks 5-12, define

24 The incidence of clinically significant thrombocytopenic events in patients receiving romiplosti

25 was the incidence of clinically significant thrombocytopenic events, defined by grade 3 or 4 thrombo

26 All thrombocytopenic groups showed evidence of impaired vasc

27 lets occurs in about 18% of immunosuppressed thrombocytopenic hematology/oncology patients and repres

28 eding remains a significant problem for many thrombocytopenic hematology/oncology patients in spite o

29 with a thrombin inhibitor became moderately thrombocytopenic in response to anti-CD40L ICs and had p

30 A systematic registry of congenitally thrombocytopenic individuals would almost certainly lead

31 lets from the bloodstream can be followed in thrombocytopenic individuals, no model exists for quanti

32 In conclusion, although thrombocytopenic ITP patients have higher baseline plate

33 g peripheral serotonin (Tph1(-/-) and immune thrombocytopenic [ITP] mice).

34 eks after transfer, the ITP SCID mice became thrombocytopenic (< 200 x 10(9) platelets/L) and had inc

35 d the Matrigel model, in four animal models: thrombocytopenic, Lyst(bg) (platelet storage pool defici

36 morrhage), inflammation, and injury, whereas thrombocytopenic Mac-1-deficient mice remained resistant

37 Many HSCT recipients are thrombocytopenic, making such procedure too risky becaus

38 that plasma FXIII-A levels were unchanged in thrombocytopenic mice (Bcl-x(Plt20/Plt20) and Mpl(-/-)),

39 Thrombocytopenic mice (platelet counts < 1% of uninfecte

40 The thrombocytopenic mice also showed more protein leakage a

41 Thrombocytopenic mice demonstrated PC-dependent enhanced

42 Surprisingly, thrombocytopenic mice exhibited no delay in the reparati

43 Compared to control mice, thrombocytopenic mice exhibited significantly altered wo

44 Platelets from thrombocytopenic mice expressing GAP-deficient Rasa3 (H7

45 is and a reduction in tumor proliferation in thrombocytopenic mice receiving chemotherapy.

46 Leukocyte recruitment in thrombocytopenic mice remained suppressed after reinfusi

47 Thrombocytopenic mice showed enhanced coagulation activa

48 Here, we subjected thrombocytopenic mice to models of dermatitis, stroke, a

49 Exposure of thrombocytopenic mice to UVB light provokes cutaneous pe

50 The number of growing vessels in the thrombocytopenic mice was lower in the cornea assay, and

51 Compared with thrombocytopenic mice, bone marrow histology in the resc

52 thelial growth factor (Vegf) were studied in thrombocytopenic mice, Tph1(-) (/) (-) mice, and through

53 t in the induction of tumor vessel injury in thrombocytopenic mice.

54 ine dinucleotide phosphate oxidase-deficient thrombocytopenic mice.

55 lammation and was not observed in uninflamed thrombocytopenic mice.

56 grity and the kinetics of skin hemorrhage in thrombocytopenic mice.

57 growth factors in the wounds of control and thrombocytopenic mice.

58 ls were higher in plasma but not in lungs of thrombocytopenic mice.

59 a Mpl-/- (thrombopoietin receptor knockout) thrombocytopenic murine model.

60 novel potential therapeutic alternative for thrombocytopenic neonates.

61 and did not increase the risk of bleeding in thrombocytopenic neonates.

62 In thrombocytopenic NPY(-/-) mice, transfusion of wild-type

63 y little neutrophil recruitment was noted in thrombocytopenic or CD41-deficient mice.

64 -beta1 was lower in mice rendered profoundly thrombocytopenic or mice with selectively low levels of

65 rease was even more pronounced in profoundly thrombocytopenic patients (31.6 +/- 10.6 units preop ver

66 In profoundly thrombocytopenic patients (preop levels < 20 K/microL),

67 As a result, a substantial number of thrombocytopenic patients are unnecessarily exposed to c

68 Antiplatelet GPIIIa49-66 Ab of HIV-related thrombocytopenic patients induces thrombocytopenia and p

69 h allows analysis of platelet aggregation in thrombocytopenic patients or infants, and facilitates st

70 This phenomenon is also observed in immune-thrombocytopenic patients when tested for UVB tolerance.

71 eltrombopag might be a treatment option for thrombocytopenic patients with AML or MDS who are inelig

72 Sera from dually infected thrombocytopenic patients with HCV and HIV-ITP reacted s

73 atelet use, and adverse clinical outcomes in thrombocytopenic patients with hematological malignant n

74 Hemophagocytosis is common in thrombocytopenic patients with sepsis, frequently includ

75 For this reason, the analysis of thrombocytopenic patients, infants, and animal models is

76 d intervals between platelet transfusions in thrombocytopenic patients.

77 l efficacy for improving platelet numbers in thrombocytopenic patients.

78 ctomy hold true even for the most profoundly thrombocytopenic patients.

79 c avenue to prevent fatal bleeding in immune-thrombocytopenic patients.

80 nzyme tryptophan hydroxylase-1, restored the thrombocytopenic phenotype.

81 y was hereditary spherocytosis (111), immune thrombocytopenic purpura (36), sickle cell disease (SCD)

82 Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare thrombo

83 dying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cleave VWF mu

84 Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platele

85 ine if megakaryocytes are targeted by immune thrombocytopenic purpura (ITP) autoantibodies, as are pl

86 treatment for adult patients with idiopathic thrombocytopenic purpura (ITP) for more than 50 years.

87 The basis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied

88 The pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediate

89 Idiopathic thrombocytopenic purpura (ITP) is a common hematologic d

90 Adult chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder

91 Chronic immune thrombocytopenic purpura (ITP) is characterised by accel

92 Chronic immune thrombocytopenic purpura (ITP) is characterized by low p

93 Immune thrombocytopenic purpura (ITP) is characterized by the p

94 Chronic immune thrombocytopenic purpura (ITP) is manifested by autoanti

95 Patients with severe immune thrombocytopenic purpura (ITP) may require an acute incr

96 FcgammaR-dependent cytopenias such as immune thrombocytopenic purpura (ITP) or autoimmune hemolytic a

97 Treatments for immune thrombocytopenic purpura (ITP) providing durable platele

98 somes as a new treatment strategy for immune thrombocytopenic purpura (ITP) through the use of a mous

99 of immune-related diseases, including immune thrombocytopenic purpura (ITP), autoimmune neuropathies,

100 ites in 23 countries with chronic idiopathic thrombocytopenic purpura (ITP), platelet counts less tha

101 s, the authors concluded that, in idiopathic thrombocytopenic purpura (ITP), production of platelets

102 er system was developed in a model of immune thrombocytopenic purpura (ITP).

103 s as well as in >80% of patients with immune thrombocytopenic purpura (ITP).

104 ment of children newly diagnosed with immune thrombocytopenic purpura (ITP).

105 ) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP).

106 the standard first-line treatment for immune thrombocytopenic purpura (ITP).

107 in-induced thrombocytopenia (HIT) and immune thrombocytopenic purpura (ITP).

108 Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led

109 asma samples from immune-mediated thrombotic thrombocytopenic purpura (iTTP) patients.

110 he acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP).

111 ith increased mortality in immune thrombotic thrombocytopenic purpura (iTTP).

112 ts, hypertension (n = 2) and immune-mediated thrombocytopenic purpura (n = 1), were possibly related

113 ich includes two major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic synd

114 Acquired thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic synd

115 Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic

116 Recovery from acute episodes of thrombotic thrombocytopenic purpura (TTP) appears complete except f

117 leading to idiopathic, autoimmune thrombotic thrombocytopenic purpura (TTP) by identifying naturally

118 The pathophysiology of thrombotic thrombocytopenic purpura (TTP) can be explained by the a

119 Thrombotic thrombocytopenic purpura (TTP) in adults is usually caus

120 Its aims are: to rule thrombotic thrombocytopenic purpura (TTP) in or out, with urgency,

121 Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

122 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

123 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening dis

124 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening hem

125 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening ill

126 Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic dis

127 Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threat

128 Gemcitabine-associated thrombotic thrombocytopenic purpura (TTP) is a rare complication of

129 Thrombotic thrombocytopenic purpura (TTP) is an acute, life-threate

130 Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation

131 Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by throm

132 Thrombotic thrombocytopenic purpura (TTP) is primarily caused by im

133 Thrombotic thrombocytopenic purpura (TTP) is the common name for ad

134 Acquired thrombotic thrombocytopenic purpura (TTP) is the consequence of a s

135 Hereditary thrombotic thrombocytopenic purpura (TTP) may be rare, but it is fo

136 (APS), atypical presentations of thrombotic thrombocytopenic purpura (TTP) or heparin-induced thromb

137 factor (VWF)-cleaving protease implicated in thrombocytopenic purpura (TTP) pathogenesis was identifi

138 c ADAMTS13 activity in congenital thrombotic thrombocytopenic purpura (TTP) patients is constrained b

139 In contrast to thrombotic thrombocytopenic purpura (TTP) patients, no aHUS patient

140 Although both aHUS and acquired thrombotic thrombocytopenic purpura (TTP) remain clinical diagnoses

141 ive treatment, most patients with thrombotic thrombocytopenic purpura (TTP) survive the acute TTP epi

142 Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over ha

143 activity is the primary cause of thrombotic thrombocytopenic purpura (TTP) whereas overwhelming acti

144 f plasma ADAMTS13 activity causes thrombotic thrombocytopenic purpura (TTP), a life-threatening syndr

145 key factor in the pathogenesis of thrombotic thrombocytopenic purpura (TTP), a life-threatening throm

146 In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated defic

147 n effective empiric treatment for thrombotic thrombocytopenic purpura (TTP), but how therapy affects

148 may precipitate acute episodes of thrombotic thrombocytopenic purpura (TTP), but pregnancy outcomes i

149 d to a life-threatening disorder, thrombotic thrombocytopenic purpura (TTP), characterized by platele

150 t advances have demonstrated that thrombotic thrombocytopenic purpura (TTP), characterized by widespr

151 ted with platelet transfusions in thrombotic thrombocytopenic purpura (TTP), heparin-induced thromboc

152 aHUS from other TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult due to over

153 immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively, illuminate

154 molytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), the histories and presen

155 In acquired thrombotic thrombocytopenic purpura (TTP), the persistence of sever

156 eatening disorder called acquired thrombotic thrombocytopenic purpura (TTP).

157 molytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).

158 iency leads to the fatal disorder thrombotic thrombocytopenic purpura (TTP).

159 pts to ameliorate the symptoms of thrombotic thrombocytopenic purpura (TTP).

160 ucial role in the pathogenesis of thrombotic thrombocytopenic purpura (TTP).

161 t life-threatening disease called thrombotic thrombocytopenic purpura (TTP).

162 of this enzyme activity leads to thrombotic thrombocytopenic purpura (TTP).

163 severe deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP).

164 to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

165 3) revolutionized our approach to thrombotic thrombocytopenic purpura (TTP).

166 d our understanding of idiopathic thrombotic thrombocytopenic purpura (TTP).

167 stic of idiopathic and HIV-linked thrombotic thrombocytopenic purpura (TTP).

168 ts with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP).

169 etalloprotease is associated with thrombotic thrombocytopenic purpura (TTP).

170 activity of the protease, causes thrombotic thrombocytopenic purpura (TTP).

171 ssociated with the development of thrombotic thrombocytopenic purpura (TTP).

172 ombosis in patients with acquired thrombotic thrombocytopenic purpura (TTP).

173 to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

174 Pregnancy can precipitate thrombotic thrombocytopenic purpura (TTP).

175 iency to complement activation in thrombotic thrombocytopenic purpura (TTP).

176 le in pathogenesis of the disease thrombotic thrombocytopenic purpura (TTP); however, experimental ev

177 TTP cases from the United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry with clinical

178 loned mAbs from two patients with thrombotic thrombocytopenic purpura and a healthy person.

179 on the status of current research in immune thrombocytopenic purpura and a preview of agents in deve

180 Third, studies on thrombotic thrombocytopenic purpura and ADAMTS13-knockout mice sugg

181 microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome,

182 us to understand pathogenesis of thrombotic thrombocytopenic purpura and other arterial thromboses a

183 ld be an antithrombotic agent for thrombotic thrombocytopenic purpura and other thrombotic conditions

184 f any treatment for patients with idiopathic thrombocytopenic purpura and persistent severe thrombocy

185 ascular occlusion associated with thrombotic thrombocytopenic purpura and sepsis was revealed by the

186 munoglobulin G from patients with thrombotic thrombocytopenic purpura and sequence alignment of the A

187 ceptable for patients with refractory immune thrombocytopenic purpura and severe thrombocytopenia wit

188 ions including arthritis, cancer, thrombotic thrombocytopenic purpura and the Ehlers-Danlos type VIIC

189 alikes and their distinction from thrombotic thrombocytopenic purpura and the hemolytic uremic syndro

190 Mutations from thrombotic thrombocytopenic purpura and von Willebrand disease prov

191 gnosis between inherited and acquired immune thrombocytopenic purpura as well as clinical practice on

192 pathy and a possible diagnosis of thrombotic thrombocytopenic purpura between Jan 8, 2004, and Dec 6,

193 Deaths have been reported for 2.9% of immune thrombocytopenic purpura cases treated with rituximab, b

194 tient suffers from a rare form of idiopathic thrombocytopenic purpura caused by a GPVI-specific autoa

195 Patients suffering from acquired thrombotic thrombocytopenic purpura develop autoantibodies directed

196 Thrombotic thrombocytopenic purpura exemplifies how von Willebrand

197 s for the diagnosis and management of immune thrombocytopenic purpura focused entirely on primary dis

198 re more than 16 years of age, had idiopathic thrombocytopenic purpura for more than 3 months, had a p

199 The treatment landscape of immune thrombocytopenic purpura has the potential for dramatic

200 the pathophysiology of idiopathic thrombotic thrombocytopenic purpura have provided the rationale for

201 unding the diagnosis and treatment of immune thrombocytopenic purpura in children continue to evolve.

202 evision of the present guidelines for immune thrombocytopenic purpura in pregnancy based on evidence-

203 Hematology and British guidelines on immune thrombocytopenic purpura incidence, prevalence, and natu

204 Treatment of chronic refractory idiopathic thrombocytopenic purpura is a dilemma because many patie

205 The diagnosis of immune thrombocytopenic purpura is a process of elimination of

206 Thrombotic thrombocytopenic purpura is a rare complication of thien

207 The acquired form of thrombotic thrombocytopenic purpura is associated with inhibitory a

208 Thrombotic thrombocytopenic purpura is caused by congenital or acqu

209 ed by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is distinguished by a severe de

210 ing protease activity in acquired thrombotic thrombocytopenic purpura is due to an autoantibody inhib

211 If the diagnosis of immune thrombocytopenic purpura is in question due to the prese

212 Refractory immune thrombocytopenic purpura is infrequent in children, but

213 about the incidence and prevalence of immune thrombocytopenic purpura is limited, with nearly all dat

214 l investigation of novel therapies in immune thrombocytopenic purpura is undergoing a revolution that

215 A diagnosis of immune thrombocytopenic purpura may be based on an evaluation o

216 Management of refractory immune thrombocytopenic purpura often requires multiple agents

217 as a second-line treatment of chronic immune thrombocytopenic purpura outside a clinical trial.

218 es to be indicated for idiopathic thrombotic thrombocytopenic purpura regardless of ADAMTS13 levels,

219 f delivery of a pregnant patient with immune thrombocytopenic purpura should be determined based on m

220 receiving alemtuzumab developed late immune thrombocytopenic purpura that remitted with standard the

221 Adults with severe thrombocytopenic purpura who responded poorly to therape

222 itors, and the risk of relapse of thrombotic thrombocytopenic purpura will be important to further va

223 ings secreted by/anchored to ECs (thrombotic thrombocytopenic purpura).

224 Thrombotic thrombocytopenic purpura, a clinical syndrome characteri

225 d a molecular distinction between thrombotic thrombocytopenic purpura, a disease characterized by a l

226 uman endothelial cells and causes thrombotic thrombocytopenic purpura, a disease with similarities to

227 insights into the pathophysiology of immune thrombocytopenic purpura, a disorder in which autoantibo

228 During therapy of thrombotic thrombocytopenic purpura, a subtype of TMAs often associ

229 0% of patients diagnosed with primary immune thrombocytopenic purpura, and are not associated with di

230 rlying Helicobacter pylori-associated immune thrombocytopenic purpura, and Ghevaert et al. describe a

231 orders, such as rheumatoid arthritis, immune thrombocytopenic purpura, autoimmune hemolytic anemia, s

232 ypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, C3GN, and dense deposit diseas

233 hritis, systemic lupus erythematosus, immune thrombocytopenic purpura, chronic cold agglutinin diseas

234 and the pathogenesis of clinical thrombotic thrombocytopenic purpura, especially in relation to ADAM

235 S13 deficiency is associated with thrombotic thrombocytopenic purpura, in which life-threatening epis

236 ia, antiphospholipid syndrome and thrombotic thrombocytopenic purpura, include immunosuppression and

237 n patients with acute episodes of thrombotic thrombocytopenic purpura, independent of ADAMTS13 activi

238 eral systemic diseases, including thrombotic thrombocytopenic purpura, manifest much of their patholo

239 management decisions in suspected thrombotic thrombocytopenic purpura, new evidence supporting the ef

240 sseminated intravascular coagulation, immune thrombocytopenic purpura, or splenic sequestration did n

241 urring in patients with inherited thrombotic thrombocytopenic purpura, resulted in a significant redu

242 associated with diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabetes among oth

243 In thrombotic thrombocytopenic purpura, the clinical impact of ADAMTS1

244 In secondary forms of immune thrombocytopenic purpura, when the hematologist plays a

245 A more common TMA is thrombotic thrombocytopenic purpura, which is caused by the lack of

246 ease platelet counts in patients with immune thrombocytopenic purpura, without significant adverse ef

247 cy, making their distinction from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome diffi

248 greatest risk for development of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is ne

249 crease the risk for occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

250 sistance, multiple sclerosis, and idiopathic thrombocytopenic purpura.

251 MPO were characteristic for acute thrombotic thrombocytopenic purpura.

252 eatening disorder called acquired thrombotic thrombocytopenic purpura.

253 mbocytopenia in patients with chronic immune thrombocytopenic purpura.

254 r microangiopathies, particularly thrombotic thrombocytopenic purpura.

255 plasma metalloprotease, leads to thrombotic thrombocytopenic purpura.

256 ances) in the pathogenesis of chronic immune thrombocytopenic purpura.

257 basis for a common bleeding disorder, immune thrombocytopenic purpura.

258 severe, acute and chronic refractory immune thrombocytopenic purpura.

259 e are many definitions for refractory immune thrombocytopenic purpura.

260 splenectomy in patients with chronic immune thrombocytopenic purpura.

261 n used to treat patients with chronic immune thrombocytopenic purpura.

262 -cleaving metalloprotease, causes thrombotic thrombocytopenic purpura.

263 is and targeting treatment of chronic immune thrombocytopenic purpura.

264 management of pregnant patients with immune thrombocytopenic purpura.

265 ne may not be sufficient to cause thrombotic thrombocytopenic purpura.

266 MTS13 activity in plasma leads to thrombotic thrombocytopenic purpura.

267 the diagnostic approach to childhood immune thrombocytopenic purpura.

268 rategies employed in the treatment of immune thrombocytopenic purpura.

269 er clarify its role in idiopathic thrombotic thrombocytopenic purpura.

270 and in an IFN-gamma-enhanced model of immune thrombocytopenic purpura.

271 be treated for these infections, not immune thrombocytopenic purpura.

272 ective means of treating acquired thrombotic thrombocytopenic purpura.

273 arin-induced thrombocytopenia and autoimmune thrombocytopenic purpura.

274 much platelet adhesion may cause thrombotic thrombocytopenic purpura.

275 refractory and relapsing cases of thrombotic thrombocytopenic purpura.

276 hophysiology differs from that of thrombotic thrombocytopenic purpura.

277 refractory and relapsing acquired thrombotic thrombocytopenic purpura.

278 cal hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

279 iciency causes a lethal syndrome, thrombotic thrombocytopenic purpura.

280 ongenital and acquired idiopathic thrombotic thrombocytopenic purpura.

281 gG from a patient with idiopathic thrombotic thrombocytopenic purpura.

282 Adamts13(-/-) mice in a model of thrombotic thrombocytopenic purpura.

283 odies against ADAMTS13 that cause thrombotic thrombocytopenic purpura.

284 enic target for autoantibodies in thrombotic thrombocytopenic purpura.

285 , a condition only experienced in thrombotic thrombocytopenic purpura.

286 while ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura.

287 ma exchange in some patients with thrombotic thrombocytopenic purpura; conversely such deficiency is

288 ish aHUS from other TMAs, such as thrombotic thrombocytopenic purpura; however, novel bioassays are b

289 ausea, grade 3 infection, grade 3 thrombotic thrombocytopenic purpurea, grade 2 nausea, grade 2 gener

290 Changes did not occur in thrombocytopenic rats, those receiving tirofiban to inhi

291 tential therapeutic strategy for controlling thrombocytopenic states.

292 enhance platelet production in a variety of thrombocytopenic states.

293 let number and platelet recovery following a thrombocytopenic stress.

294 tected in sKitL-deficient Mmp9-/- as well as thrombocytopenic Thpo-/- and TPO receptor-deficient (Mpl

295 ory sites are the cellular culprits inducing thrombocytopenic tissue hemorrhage.

296 y and/or chemically inhibited platelets into thrombocytopenic (TP) mice.

297 IL-11, did not induce platelet production in thrombocytopenic, TPO-deficient (Thpo(-/-)) or TPO recep

298 ocytopenic VWD type 2B mice, suggesting that thrombocytopenic VWD type 2B mice were elevated two- to

299 VWF was exclusively detected on platelets of thrombocytopenic VWD type 2B mice, suggesting that throm

300 platelet consumption data obtained in WT and thrombocytopenic WASP(-) mice.